Lexicon Pharmaceuticals | LXRX - Cost Of Sales


Lexicon Pharmaceuticals reported $201K in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Abbott USD 5.94B 642M Jun/2026
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Akebia Therapeutics USD 10.34M 441K Dec/2025
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Coherus Biosciences USD 4.04M 324K Dec/2025
Eli Lilly USD 3.27B 309M Jun/2026
Halozyme Therapeutics USD 108.68M 67K Jun/2026
Illumina USD 389M 19M Jun/2026
Insmed USD 69.29M 19.79M Jun/2026
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
J&J USD 8.08B 80M Sep/2026
Lexicon Pharmaceuticals USD 201K 191K Dec/2025
MacroGenics USD 9.53M 585K Mar/2026
MannKind USD 34.21M 5.38M Jun/2026
Merck USD 3.14B 200M Jun/2026
Moderna USD 93M 862M Jun/2026
Novartis USD 3.71B 251M Jun/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Thermo Fisher Scientific USD 7.54B 577M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
United Therapeutics USD 99.5M 33.9M Jun/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024